Drug Trial Radar · NCT00297102
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)
Last checked: Nov 19, 2026Latest source record: Jan 16, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,523
Actual
Start
Feb 2006
Primary completion
Jul 2008
Study completion Sep 2008
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 28, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to investigate the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily in the morning at one dose level. The study duration will last up to 56 weeks. The study will provide further data on safety and tolerability of roflumilast. For additional information (for US patients only) see www.COPDSTUDY.net or dial 866-788-2673 (toll free).
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
RoflumilastDrug
500 mcg, once daily, oral administration in the morning
PlaceboDrug
once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)Time frame: Change from baseline over 52 weeks of treatment
- COPD Exacerbation Rate (Moderate or Severe)Time frame: 52 weeks treatment period
Locations
179 sites in 11 countries. Site status is shown where the registry gives one.
Altana Pharma/Nycomed Investigational Site
Fullerton, California
Altana Pharma/Nycomed Investigational Site
Los Angeles, California
Altana Pharma/Nycomed Investigational Site
Los Angeles, California
Altana Pharma/Nycomed Investigational Site
Palmdale, California
Altana Pharma/Nycomed Investigational Site
Rancho Mirage, California
Altana Pharma/Nycomed Investigational Site
San Diego, California
Altana Pharma/Nycomed Investigational Site
Bay Pines, Florida
Altana Pharma/Nycomed Investigational Site
Miami, Florida
Altana Pharma/Nycomed Investigational Site
Panama City, Florida
Altana Pharma/Nycomed Investigational Site
Atlanta, Georgia
Altana Pharma/Nycomed Investigational Site
Marietta, Georgia
Altana Pharma/Nycomed Investigational Site
Hines, Illinois
Altana Pharma/Nycomed Investigational Site
South Bend, Indiana
Altana Pharma/Nycomed Investigational Site
Lebanon, Kentucky
Altana Pharma/Nycomed Investigational Site
Metairie, Louisiana
Altana Pharma/Nycomed Investigational Site
New Orleans, Louisiana
Altana Pharma/Nycomed Investigational Site
Slidell, Louisiana
Altana Pharma/Nycomed Investigational Site
Sunset, Louisiana
Altana Pharma/Nycomed Investigational Site
Bangor, Maine
Altana Pharma/Nycomed Investigational Site
Baltimore, Maryland
Altana Pharma/Nycomed Investigational Site
North Dartmouth, Massachusetts
Altana Pharma/Nycomed Investigational Site
Edina, Minnesota
Altana Pharma/Nycomed Investigational Site
Minneapolis, Minnesota
Altana Pharma/Nycomed Investigational Site
Chesterfield, Missouri
Altana Pharma/Nycomed Investigational Site
St Louis, Missouri
Altana Pharma/Nycomed Investigational Site
Billings, Montana
Altana Pharma/Nycomed Investigational Site
Missoula, Montana
Altana Pharma/Nycomed Investigational Site
Lincoln, Nebraska
Altana Pharma/Nycomed Investigational Site
Omaha, Nebraska
Altana Pharma/Nycomed Investigational Site
Reno, Nevada
Altana Pharma/Nycomed Investigational Site
Cherry Hill, New Jersey
Altana Pharma/Nycomed Investigational Site
Springfield, New Jersey
Altana Pharma/Nycomed Investigational Site
New York, New York
Altana Pharma/Nycomed Investigational Site
Winston-Salem, North Carolina
Altana Pharma/Nycomed Investigational Site
Cincinnati, Ohio
Altana Pharma/Nycomed Investigational Site
Columbus, Ohio
Altana Pharma/Nycomed Investigational Site
Toledo, Ohio
Altana Pharma/Nycomed Investigational Site
Youngstown, Ohio
Altana Pharma/Nycomed Investigational Site
Lake Oswego, Oregon
Altana Pharma/Nycomed Investigational Site
Philadelphia, Pennsylvania
Showing 40 of 179 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.